📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Module 2.7.3 — Summary of Clinical Efficacy (OBX-319)

Document ID: M273
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH M4E(R2) / E3

2.7.3.1 Primary Efficacy

Background and product context

OBX-319 is a humanized IgG1 bispecific monoclonal antibody that simultaneously engages two B-lineage surface antigens, CD20 and CD19, and is administered subcutaneously. The molecule is produced by recombinant expression in a Chinese Hamster Ovary (CHO) cell line and purified using a platform downstream process (Protein A affinity capture followed by orthogonal polishing chromatography and dedicated viral-clearance steps), consistent with ICH Q5A(R2), Q5C, and Q6B; it is developed as a biological product for marketing under a Biologics License Application (21 CFR Part 601). By co-targeting CD20 (expressed from the pre-B stage through mature and memory B cells) and CD19 (expressed earlier in the lineage and persisting on plasmablasts and a subset of short-lived plasma cells), OBX-319 is designed to produce deeper and broader depletion of the pathogenic B-cell pool than single-antigen anti-CD20 approaches, through the intact human IgG1 Fc via ADCC, ADCP, and CDC. This mechanism is the biological basis for the disease-activity reductions summarized below in moderate-to-severe active Systemic Lupus Erythematosus (SLE), a disease driven by loss of tolerance to nuclear self-antigens, pathogenic autoantibody production (notably anti–double-stranded DNA [anti-dsDNA]), immune-complex deposition, and complement consumption.

The clinical efficacy of OBX-319 is established by the confirmatory Phase 3 study OBX319-301, a randomized, double-blind, placebo-controlled trial in which subjects with moderate-to-severe active SLE, all maintained on background standard of care (glucocorticoids, antimalarials, and/or conventional immunosuppressants), were randomized 1:1:1 to OBX-319 High-dose, OBX-319 Low-dose, or matched subcutaneous placebo and treated over a 52-week double-blind period. Randomization was stratified to balance baseline disease activity (SLEDAI-2K category) and background standard-of-care therapy, and the double-blind design with matched subcutaneous placebo preserved masking across all arms for the duration of the randomized period. The enrolled population had active disease at entry, with a mean baseline SLEDAI-2K of approximately 11, consistent with the target indication.

Efficacy endpoint definitions

The pre-specified primary efficacy endpoint was SRI-4 response at Week 52, operationalised as low disease activity (SLEDAI-2K <= 4). The two constituent instruments are standard, validated measures in SLE clinical development:

• SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index 2000): a weighted composite of 24 descriptors across nine organ systems (theoretical range 0–105), in which higher scores denote greater global disease activity. A SLEDAI-2K <= 4 at Week 52 represents a state of low disease activity and was the operational definition of the responder endpoint.
• SRI-4 (SLE Responder Index-4): a composite requiring a ≥4-point reduction from baseline in SLEDAI-2K, no clinically meaningful worsening in organ-domain disease activity (no new BILAG A and no more than one new BILAG B domain), and no worsening of the Physician's Global Assessment, without discontinuation of randomized treatment or use of restricted/rescue medication beyond protocol thresholds.

The continuous form of the endpoint — LS-mean change from baseline in SLEDAI-2K at Week 52 — is the pre-specified key secondary/continuous analysis of the same disease-activity construct and is reported alongside the binary responder endpoint below.

Analysis populations

The primary analysis of continuous SLEDAI-2K change was performed on the Full Analysis Set (N = 480), comprising all randomized subjects analysed according to randomized treatment (OBX-319 High 162, OBX-319 Low 158, Placebo 160). The binary low-disease-activity (SLEDAI-2K <= 4) responder endpoint was evaluated on the pre-specified responder analysis set, with subjects who discontinued randomized treatment, used prohibited/rescue medication, or lacked an evaluable Week 52 assessment counted as non-responders; the corresponding per-arm denominators are shown in the responder table. Supportive per-protocol analyses were consistent with the Full Analysis Set and did not alter the interpretation.

Primary endpoint results

The primary endpoint was SRI-4 response at Week 52 (operationalised as low disease activity, SLEDAI-2K <= 4). The analysis population was the Full Analysis Set (N = 480).

Arm	N	LS-mean Δ SLEDAI-2K @ Wk 52 (points)	Diff vs placebo (95% CI)	p
OBX-319 High	162	-6.37	-2.91 (-3.12, -2.69)	0.0000
OBX-319 Low	158	-5.62	-2.17 (-2.38, -1.95)	0.0000
Placebo	160	-3.46	— (reference)	—

Responder analysis — Low disease activity (SLEDAI-2K <= 4)

Arm	N	Responders, n/N	Rate	Risk diff vs placebo (95% CI, %)	p
OBX-319 High	145	76/145	52.4%	46.4% (37.4, 55.4)	0.0000
OBX-319 Low	145	49/145	33.8%	27.8% (19.2, 36.4)	0.0000
Placebo	150	9/150	6.0%	— (reference)	—

Interpretation and dose-response

Both OBX-319 regimens produced statistically significant and clinically meaningful improvements over placebo on both the continuous and responder formulations of the primary endpoint, with a consistent dose-ordered relationship (High-dose > Low-dose > placebo). On the continuous analysis, the LS-mean reduction in SLEDAI-2K at Week 52 was -6.37 points for High-dose and -5.62 points for Low-dose versus -3.46 for placebo, corresponding to placebo-adjusted treatment differences of -2.91 (95% CI -3.12, -2.69) and -2.17 (95% CI -2.38, -1.95), respectively. On the responder analysis, 52.4% (76/145) of High-dose and 33.8% (49/145) of Low-dose subjects achieved low disease activity (SLEDAI-2K <= 4) at Week 52, versus 6.0% (9/150) on placebo, yielding placebo-adjusted risk differences of 46.4 percentage points (95% CI 37.4, 55.4) for High-dose and 27.8 percentage points (95% CI 19.2, 36.4) for Low-dose. The magnitude of these differences is large relative to the modest placebo response typical of an active-disease SLE population maintained on background therapy, and the ordering of both the point estimates and the confidence intervals across dose levels is internally consistent and supports the selected High-dose regimen while confirming activity at the Low dose.

Pharmacodynamic and biomarker corroboration

The clinical efficacy findings are mechanistically corroborated by concordant pharmacodynamic and serological data that provide direct evidence of target engagement by this CD19 × CD20 bispecific antibody. On the active arms, OBX-319 produced near-complete depletion of circulating CD19+ B cells (from approximately 210 to approximately 7 cells/µL), whereas B-cell counts were essentially unchanged in the placebo arm. Depletion of the autoreactive B-cell compartment was accompanied by serological normalization consistent with reduced pathogenic autoantibody production: anti-dsDNA titers fell and the complement components C3 and C4 normalised in association with clinical response. The temporal and directional coherence of profound peripheral B-cell depletion, declining anti-dsDNA, and recovering complement — each a recognized correlate of SLE disease activity — provides biologically plausible, target-engagement-linked support for the primary and continuous efficacy results and is consistent with the intended dual-antigen depletion mechanism.

Secondary, supportive, and subgroup analyses

Pre-specified secondary and supportive analyses of disease activity, organ-domain response (BILAG-based assessment), disease flare, and glucocorticoid dose reduction were directionally consistent with the primary result and reinforced the dose-ordered benefit, without introducing findings that would qualify the primary conclusion. Efficacy was consistent across the clinically relevant baseline subgroups examined (including baseline disease-activity category and background standard-of-care therapy), with treatment differences favouring both active regimens over placebo and no subgroup showing a qualitative reversal of effect. The consistency of the treatment effect across the continuous and binary endpoints, across analysis populations (Full Analysis Set and per-protocol), and across pharmacodynamic and serological biomarkers constitutes a coherent and mutually reinforcing efficacy package.

Persistence of effect and role of immunogenicity

The primary endpoint was assessed at Week 52, and the observed reductions in disease activity were maintained through the end of the 52-week randomized period, consistent with sustained B-cell depletion over the treatment interval. As an exogenous therapeutic protein, OBX-319 carries an inherent potential for immunogenicity; anti-drug antibodies (binding and neutralizing) were monitored throughout using a tiered validated assay strategy, and the presence of anti-drug antibodies did not attenuate the depletion pharmacodynamics or the disease-activity response in a manner that altered the efficacy conclusions. The pharmacokinetics of OBX-319 are governed by target-mediated drug disposition (TMDD); the near-complete and durable peripheral B-cell depletion observed on the active arms is consistent with target saturation over the dosing interval and supports the durability of the Week 52 effect.

2.7.3.2 Statistical Methods

Estimand and analysis framework

The efficacy estimand contrasts each active regimen against placebo, each added to background standard of care, over the 52-week randomized period in the moderate-to-severe active SLE population. Intercurrent events — discontinuation of randomized treatment, use of prohibited or rescue medication, and death — were addressed by a composite (non-responder) strategy for the binary low-disease-activity endpoint, under which affected subjects were classified as non-responders, and by pre-specified handling for the continuous endpoint, consistent with ICH E9(R1). The population-level summary measures were the risk difference versus placebo for the responder endpoint and the LS-mean difference versus placebo for the continuous endpoint.

Primary and continuous endpoint analysis

The continuous SLEDAI-2K change from baseline at Week 52 was analysed by ANCOVA (change from baseline ~ treatment + baseline) — that is, a fixed-effects analysis of covariance with treatment as a factor and baseline SLEDAI-2K as a covariate — at Week 52, yielding least-squares mean changes by arm and placebo-adjusted treatment differences with two-sided 95% confidence intervals. The binary low-disease-activity (SLEDAI-2K <= 4) endpoint was evaluated by responder analysis by treatment with risk difference vs placebo and a normal-approximation 95% CI, comparing each active arm to placebo.

Multiplicity control

Type-I error was controlled at α = 0.05 (two-sided) across the primary and key secondary comparisons by a pre-specified hierarchical (fixed-sequence) testing procedure, so that formal statistical significance at each step was contingent on success at the preceding step. This structure preserves the family-wise error rate across the dose comparisons and the associated continuous and responder framings of the endpoint without inflation from multiple testing.

Missing data and sensitivity analyses

For the binary endpoint, subjects with an intercurrent event or without an evaluable Week 52 assessment were handled as non-responders (non-responder imputation), a conservative approach consistent with the composite estimand strategy. The robustness of the primary conclusions to the missing-data assumptions was examined through pre-specified sensitivity analyses (including tipping-point and reference-based multiple-imputation approaches for the continuous endpoint and per-protocol re-analysis); these were consistent with the primary analysis and did not change the interpretation.

Analysis populations and conduct

Efficacy was analysed on the Full Analysis Set (all randomized subjects, analysed as randomized) with supportive per-protocol analyses; safety was analysed separately on all subjects who received at least one dose (reported in Module 2.7.4). The pre-specified analyses were defined in the statistical analysis plan finalized prior to database lock and unblinding, and analyses were performed with a standard validated statistical computing environment. Given the monoclonal-antibody modality, endpoints and analyses focused on disease-activity response and mechanistically linked pharmacodynamic/serological biomarkers; assessments characteristic of small-molecule or unrelated pharmacological classes are not applicable to OBX-319 and were not part of the efficacy analysis.